The Pharma Data

APRIL 4, 2023

The approval includes all indications covered by the reference medicine*: rheumatic diseases, Crohn’s disease, ulcerative colitis, plaque psoriasis, uveitis and hidradenitis suppurativa. 1 “Living with a chronic disease can take a significant toll on a patient’s quality of life.

Biosimilars 40

Biosimilars Pharmacokinetics FDA Approval Packaging 40

Drug Channels

OCTOBER 17, 2022

Copyright © 2006-2022 Pembroke Consulting, Inc. Don’t miss the chance to unite with colleagues and master the complexities of pharmacy and distribution models to accelerate patient access! The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Biosimilars 75

Biosimilars Pharmacy Therapies Production 75

Drug Channels

JULY 11, 2022

Director, Cell Therapy Operations and Patient Services, Gamida Cell Austin Fisher, Executive Director, CART Patient Support and Distribution, Autolus Chris Boneham, Vice President Market Access U.S., Copyright © 2006-2022 Pembroke Consulting, Inc. Drug Channels, or any of its employees. d/b/a Drug Channels Institute.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Compliance 98

The Pharma Data

JULY 15, 2021

The access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE). The browser can be accessed via [link]. About AbbVie.

Disease 52

Disease Biosimilars Government Treatment 52

The Pharma Data

JULY 8, 2021

Today, access to the world’s largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. Nasdaq: BIIB) and Pfizer (NYSE: PFE). The browser can be accessed via [link]. About AbbVie. About Biogen.

Disease 52

Disease Government Clinical Trials Research 52

The Pharma Data

DECEMBER 21, 2020

Severe asthma is a complex, heterogenous disease and many patients continue to face debilitating symptoms despite receiving standard of care inhaled medicines and currently approved biologics. 2,3 Expression of TSLP is increased in the airways of patients with asthma and has been correlated with disease severity.

Trials 40

Trials Production Clinical Trials Government 40

Agency IQ

JULY 28, 2023

A big legislative question about PAHPA Reauthorization : The Pandemic and All-Hazards Preparedness Act (PAHPA) was originally passed in 2006. That would leave 19% of staff affected by furloughs. We’ll be most interested to see how FDA plans to handle these risk control measures in a way to reduce the risk of drug shortages.

FDA 40

FDA Science Biosimilars Regulations 40